Age 0 3 0 3 B-age
above 4 9 4 9 O
or 10 12 10 12 O
equal 13 18 13 18 O
to 19 21 19 21 O
18 22 24 22 24 B-lower_bound
years 25 30 25 30 I-lower_bound

Anticoagulant 0 13 31 44 B-treatment
medication 14 24 45 55 I-treatment
of 25 27 56 58 O
any 28 31 59 62 O
kind 32 36 63 67 O
; 36 37 67 68 O
especially 38 48 69 79 O
Ascal 49 54 80 85 B-treatment
® 54 55 85 86 I-treatment
(and 55 59 86 90 O
derivates 60 69 91 100 O
) 69 70 100 101 O
, 70 71 101 102 O
coumarines 72 82 103 113 B-treatment
( 83 84 114 115 O
Sintrom 84 91 115 122 B-treatment
® 91 92 122 123 I-treatment
and 93 96 124 127 O
Marcoumar 97 106 128 137 B-treatment
® 106 107 137 138 I-treatment
) 107 108 138 139 O
, 108 109 139 140 O
all 110 113 141 144 O
heparin 114 121 145 152 B-treatment
and 122 125 153 156 O
heparin 126 133 157 164 O
- 133 134 164 165 O
like 134 138 165 169 O
formulations 139 151 170 182 O

Biopsy 0 6 183 189 B-treatment
proven 7 13 190 196 O
MLS 14 17 197 200 B-chronic_disease
( 18 19 201 202 O
including 19 28 202 211 O
the 29 32 212 215 O
reciprocal 33 43 216 226 B-treatment
chromosomal 44 55 227 238 I-treatment
translocation 56 69 239 252 I-treatment
t(12;16)(q13;p11 70 86 253 269 O
) 86 87 269 270 O
; 87 88 270 271 O
A 89 90 272 273 O
the 91 94 274 277 O
primary 95 102 278 285 B-cancer
sarcoma 103 110 286 293 I-cancer
in 111 113 294 296 O
case 114 118 297 301 O
of 119 121 302 304 O
non 122 125 305 308 B-cancer
- 125 126 308 309 I-cancer
metastatic 126 136 309 319 I-cancer
disease 137 144 320 327 I-cancer
for 145 148 328 331 O
management 149 159 332 342 O
is 160 162 343 345 O
with 163 167 346 350 O
curative 168 176 351 359 O
intent 177 183 360 366 O
( 184 185 367 368 O
regimen 185 192 368 375 O
to 193 195 376 378 O
be 196 198 379 381 O
chosen 199 205 382 388 O
= 206 207 389 390 O
18 208 210 391 393 O
x 211 212 394 395 O
2 213 214 396 397 O
GY 215 217 398 400 O
) 217 218 400 401 O
B 219 220 402 403 O
in 221 223 404 406 O
case 224 228 407 411 O
of 229 231 412 414 O
oligometastatic 232 247 415 430 B-cancer
patients 248 256 431 439 O
, 256 257 439 440 O
the 258 261 441 444 O
metastasis 262 272 445 455 O
may 273 276 456 459 O
also 277 281 460 464 O
be 282 284 465 467 O
irradiated 285 295 468 478 O
to 296 298 479 481 O
a 299 300 482 483 O
dose 301 305 484 488 O
of 306 308 489 491 O
36 309 311 492 494 B-treatment
GY 312 314 495 497 I-treatment
in 315 317 498 500 O
order 318 323 501 506 O
to 324 326 507 509 O
postpone 327 335 510 518 O
the 336 339 519 522 O
time 340 344 523 527 O
interval 345 353 528 536 O
to 354 356 537 539 O
next 357 361 540 544 O
systemic 362 370 545 553 B-treatment
chemotherapy 371 383 554 566 I-treatment
. 383 384 566 567 O
These 385 390 568 573 O
patients 391 399 574 582 O
are 400 403 583 586 O
usually 404 411 587 594 O
not 412 415 595 598 O
operated 416 424 599 607 O
upon 425 429 608 612 O
and 430 433 613 616 O
the 434 437 617 620 O
total 438 443 621 626 O
dose 444 448 627 631 O
may 449 452 632 635 O
also 453 457 636 640 O
be 458 460 641 643 O
reached 461 468 644 651 O
in 469 471 652 654 O
12 472 474 655 657 O
times 475 480 658 663 O
3 481 482 664 665 O
Gy 483 485 666 668 O
, 485 486 668 669 O
for 487 490 670 673 O
convenience 491 502 674 685 O
purposes 503 511 686 694 O
( 512 513 695 696 O
see 513 516 696 699 O
paragraph 517 526 700 709 O
10 527 529 710 712 O
for 530 533 713 716 O
radiobiological 534 549 717 732 O
considerations 550 564 733 747 O
) 564 565 747 748 O

ECOG 0 4 749 753 B-clinical_variable
( 5 6 754 755 I-clinical_variable
Eastern 6 13 755 762 I-clinical_variable
Cooperative 14 25 763 774 I-clinical_variable
Oncology 26 34 775 783 I-clinical_variable
Group 35 40 784 789 I-clinical_variable
) 40 41 789 790 I-clinical_variable

PS 0 2 791 793 B-clinical_variable
( 3 4 794 795 I-clinical_variable
Performance 4 15 795 806 I-clinical_variable
Status 16 22 807 813 I-clinical_variable
) 22 23 813 814 I-clinical_variable
0 24 25 815 816 B-lower_bound
- 25 26 816 817 O
2 26 27 817 818 B-upper_bound

Patients 0 8 819 827 O
must 9 13 828 832 O
be 14 16 833 835 O
able 17 21 836 840 O
( 22 23 841 842 O
physically 23 33 842 852 O
, 33 34 852 853 O
mentally 35 43 854 862 O
and 44 47 863 866 O
socially 48 56 867 875 O
) 56 57 875 876 O
to 58 60 877 879 O
complete 61 69 880 888 O
a 70 71 889 890 O
series 72 78 891 897 O
of 79 81 898 900 O
RT 82 84 901 903 O
, 84 85 903 904 O
followed 86 94 905 913 O
by 95 97 914 916 O
an 98 100 917 919 O
observation 101 112 920 931 B-clinical_variable
period 113 119 932 938 I-clinical_variable
of 120 122 939 941 O
4 123 124 942 943 B-lower_bound
- 124 125 943 944 O
6 125 126 944 945 B-upper_bound
weeks 127 132 946 951 I-upper_bound
and 133 136 952 955 O
undergo 137 144 956 963 O
surgery 145 152 964 971 B-treatment

Pregnancy 0 9 972 981 B-pregnancy

Prior 0 5 982 987 B-treatment
radiotherapy 6 18 988 1000 I-treatment
to 19 21 1001 1003 I-treatment
the 22 25 1004 1007 I-treatment
target 26 32 1008 1014 I-treatment
area 33 37 1015 1019 I-treatment

patients 0 8 1020 1028 O
on 9 11 1029 1031 O
anticoagulant 12 25 1032 1045 B-treatment
medication 26 36 1046 1056 I-treatment
as 37 39 1057 1059 O
described 40 49 1060 1069 O
above 50 55 1070 1075 O
may 56 59 1076 1079 O
take 60 64 1080 1084 O
part 65 69 1085 1089 O
in 70 72 1090 1092 O
the 73 76 1093 1096 O
dose 77 81 1097 1101 O
reduction 82 91 1102 1111 O
part 92 96 1112 1116 O
of 97 99 1117 1119 O
the 100 103 1120 1123 O
study 104 109 1124 1129 O
, 109 110 1129 1130 O
but 111 114 1131 1134 O
the 115 118 1135 1138 O
repeat 119 125 1139 1145 O
biopsies 126 134 1146 1154 O
may 135 138 1155 1158 O
not 139 142 1159 1162 O
be 143 145 1163 1165 O
taken 146 151 1166 1171 O

